Ruptured abdominal aortic aneurysm: lower mortality with endovascular treatment at an experienced center.

Original title: Mortality from ruptured abdominal aortic aneurysms: clinical lessons from a comparison of outcomes in England and the USA. Reference: Karthikesalingam A et al. Lancet. 2014;383:963-969.

Treatment strategy for rAAA patients may vary according to the different centers. This study analyzed in-hospital mortality, and mortality after intervention of all patients admitted with rAAA between 2005 and 2010 in USA (n=23838) and compared outcomes with a similar population in England (n=11799). 

Global in-hospital mortality was lower in the USA than in England (53.05% vs. 65.9%; p<0.0001); however, looking into patients that received some kind of intervention, mortality was similar (41.7% vs 41.6%).

Interventions (conventional surgical or endovascular repair) were more frequent in USA than in England (80.4% vs 58.4%; p<0.001), as frequent were specifically endovascular interventions (20.8% vs 8.5%, p<0.0001). These differences persisted after aged matched and sex matched comparisons.

In both countries, mortality decreased with endovascular treatment. Center experience in endovascular repair and weekday admission were also predictors of lower mortality.

Conclusion

In-hospital survival and intervention rates (especially endovascular) are lower in England than in USA for patients admitted with rAAA. Patients that received endovascular treatment saw lower mortality rates.

Editorial Comment

The absence of follow up beyond hospital discharge is a limitation to this study, as it is the lack of data on anatomical characteristics or clinical status in deciding between conventional surgical strategy vs. endovascular repair with prosthesis.

As in most cases, prevention with a relatively simple screening to allow programmed treatment would greatly reduce mortality for AAA and save the efforts it requires once ruptured. In the event of rupture, the best strategy to reduce mortality seems to be endovascular treatment in an experienced center.

SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...